Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome

Claire Meyniel, Timothy Spelman, Vilija G Jokubaitis, Maria Trojano, Guillermo Izquierdo, François Grand’Maison, Celia Oreja-Guevara, Cavit Boz, Alessandra Lugaresi, Marc Girard, Pierre Grammond, Gerardo Iuliano, Marcela Fiol, Jose Antonio Cabrera-Gomez, Ricardo Fernandez-Bolanos, Giorgio Giuliani, Jeannette Lechner-Scott, Edgardo Cristiano, Joseph Herbert, Tatjana Petkovska-Boskova, Roberto Bergamaschi, Vincent van Pesch, Fraser Moore, Norbert Vella, Mark Slee, Vetere Santiago, Michael Barnett, Eva Havrdova, Carolyn Young, Carmen-Adella Sirbu, Mary Tanner, Michelle Rutherford, Helmut Butzkueven and on behalf of the MSBasis Study Group

PLOS ONE, 2012, vol. 7, issue 6, 1-8

Abstract: Objectives: We conducted a prospective study, MSBASIS, to assess factors leading to first treatment discontinuation in patients with a clinically isolated syndrome (CIS) and early relapsing-remitting multiple sclerosis (RRMS). Methods: The MSBASIS Study, conducted by MSBase Study Group members, enrols patients seen from CIS onset, reporting baseline demographics, cerebral magnetic resonance imaging (MRI) features and Expanded Disability Status Scale (EDSS) scores. Follow-up visits report relapses, EDSS scores, and the start and end dates of MS-specific therapies. We performed a multivariable survival analysis to determine factors within this dataset that predict first treatment discontinuation. Results: A total of 2314 CIS patients from 44 centres were followed for a median of 2.7 years, during which time 1247 commenced immunomodulatory drug (IMD) treatment. Ninety percent initiated IMD after a diagnosis of MS was confirmed, and 10% while still in CIS status. Over 40% of these patients stopped their first IMD during the observation period. Females were more likely to cease medication than males (HR 1.36, p = 0.003). Patients treated in Australia were twice as likely to cease their first IMD than patients treated in Spain (HR 1.98, p = 0.001). Increasing EDSS was associated with higher rate of IMD cessation (HR 1.21 per EDSS unit, p

Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038661 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 38661&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0038661

DOI: 10.1371/journal.pone.0038661

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().